Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

Antibody-drug conjugates (ADCs) have exhibited potent clinical benefits in cancer therapy. However, development of ADCs against epidermal growth factor receptor (EGFR) has limitations because of wide expression of EGFR in both normal and tumor tissues. Previously, we developed an anti-EGFR protease-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:MAbs
Prif Awduron: Yang, Yun, Guo, Qingcheng, Chen, Xi, Zhang, Junjie, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Li, Bohua, Guo, Yajun, Wang, Hao
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2016
Pynciau:
Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966596/
https://ncbi.nlm.nih.gov/pubmed/26760045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1127491
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg